Emmanuele

$TGTX SubQ Phase 3 trial is randomized and open-label. If not mistaken, by week 24, and after AUC measurement (Primary endpoint) Co. should have an idea about it's effectiveness, before YE26/1Q27. Of course, there will be other endpoints which will take it to the 26/27 target.

Cell and gene therapy developers shouldn’t have to guess about what safety studies FDA wants to see. Today, FDA issued clear draft guidance that will save developers millions of dollars and years of effort, accelerating treatments to patients. Every effort to move more efficiently here is worth it.

$TGTX JP Morgan $TGTX OW Momentum Could Start to Build Heading into SubQ Readout: The SubQ data around YE26/1Q27 will unlock the ability for Briumvi to tap into the subQ segment. Based on investor feedback, we expect shares to regain traction approaching this catalyst.

$tgtx another big detail just noticed. In cohort 1 - 62% experienced the “crap gap” with Ocrevus In cohort 2 - 57% experience the “crap gap” With Ocrevus This is super high & all wud b potential switches imho. That’s a huge positive

$TGTX corresponding to recent study published in the journal MSology, a whopping 61% of Ocrevus patients in the study experienced the dreaded "crap gap." That's a pretty significant percentage!